Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
Following publication of the original article [1], the authors reported an error in their listed affiliations.
Main Authors: | Bin Zhao, Hong Zhao, Jiaxin Zhao |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | http://link.springer.com/article/10.1186/s40425-018-0487-7 |
Similar Items
-
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
by: Bin Zhao, et al.
Published: (2018-10-01) -
Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer
by: Bin Zhao, et al.
Published: (2020-02-01) -
Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
by: Zhou S, et al.
Published: (2019-01-01) -
Serious Neurological Adverse Events of Ceftriaxone
by: Clémence Lacroix, et al.
Published: (2021-05-01) -
Incidence and Risk of Fatal Adverse Events in Cancer Patients Treated With Vascular Endothelial Growth Factor Receptor 2-Targeted Agents: A Meta-Analysis With Trial Sequential Analysis of Randomized Controlled Trials
by: Bin Zhao, et al.
Published: (2019-08-01)